PREDICtors for Quality of Life After Sigmoidectomy for DIVerticular Disease (PREDIC-DIV)

September 7, 2023 updated by: Dr. Maximilian Sohn, Städtisches Klinikum München GmbH

PREDICtors for Health Related Quality of Life After Elective Sigmoidectomy for DIVerticular Disease: The PREDIC-DIV Study

To identify predictors for postoperative health related quality of life after elective sigmoidectomy for diverticular disease.

Study Overview

Status

Recruiting

Detailed Description

According to current international guidelines, indications for surgical treatment of diverticular disease are inhomogeneous. To date, the measurement of pre- and postoperative quality of life (QoL) is underrepresented. To ensure an individually tailored therapeutical approach, and to avoid unnecessary surgery as well as the risk of a hazardous chronification of the disease, QoL importantly needs to be focused within the decisional process for the best treatment option. The aim of the PREDIC DIV-Study is, to identify predictors for a better postoperative quality of life in patients who undergo elective sigmoidectomy for diverticular disease. PREDIC DIV is a prospective observational study.

Study Type

Observational

Enrollment (Estimated)

165

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Bavaria
      • Munich, Bavaria, Germany, 81925
        • Recruiting
        • Klinik für Allgemein- Viszeral-, Endokrine- und Minimalinvasive Chirurgie, Klinikum Bogenhausen, Städtisches Klinikum München GmbH
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

All patients > 18 years, matching to inclusion and exclusion criteria, who are scheduled for elective sigmoidectomy for diverticular disease

Description

Inclusion Criteria:

  • patients, scheduled for elective sigmoidectomy for diverticular disease (Indication: foregoing acute diverticulitis with pericolic or pelvic abscess >1cm, ongoing complaints after acute uncomplicated diverticulitis, recurrent uncomplicated disease (three or more diverticulitis episodes in combination with the patients wish for surgery), recurrent complicated disease (three or more diverticulitis episodes+complications: stenosis, fistula, chronic pain), urgent wish of patients for surgery after uncomplicated disease.
  • Age >18 years
  • ASA 1-3
  • informed consent

Exclusion Criteria:

  • Age <18 years
  • ASA 4
  • acute diverticulitis with free perforation
  • acute or forgoing diverticular bleeding
  • colorectal malignancies (current or foregoing)
  • immunosuppression (corticoids > 20 mg prednisolon/d, status post transplant)
  • advanced malignancy with systemic metastases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative quality of life (QoL) after a follow up of six month: GI-Quality of Life Index
Time Frame: six month
Quality of life will be assessed by use of the GI-Quality of Life Index
six month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative quality of life (QoL) after a follow up of six month: SF36
Time Frame: six month
Quality of life will be assessed by use of the SF36-questionnaire
six month
Postoperative quality of life (QoL) after a follow up of six month: Visual analogue scale (VAS)
Time Frame: six month
Quality of life will be assessed by use of a visual analogue scale (VAS). The scale ranges from 0 to 100 mm. 0 is the least desirable condition. 100 is the most desirable condition.
six month
Quality of life after a follow up of 24 month: SF-36
Time Frame: 24 month
Quality of life will be assessed by use of SF36-questionnaire
24 month
Quality of life after a follow up of 24 month: GI-Quality of Life Index
Time Frame: 24 month
Quality of life will be assessed by use GI-Quality of Life index-questionnaire
24 month
Quality of life after a follow up of 24 month: Visual analogue scale (VAS)
Time Frame: 24 month
Quality of life will be assessed by use of a visual analogue scale (VAS). The scale ranges from 0 to 100 mm. 0 is the least desirable condition. 100 is the most desirable condition.
24 month
Peri- und postoperative morbidity
Time Frame: 30 days, 6 and 24 month
Assessement by use of Clavien-Dindo-Classification
30 days, 6 and 24 month
Mortality
Time Frame: 30 days, 6 and 24 month
Mortality is defined as 30-days postoperative mortality and mortality in association to diverticulitis recurrency
30 days, 6 and 24 month
Coexisting characteristics of irritable bowel syndrome (IBS)
Time Frame: 0, 6 and 24 month
IBS-scoring will be performed pre- and postoperatively by use of ROME IV criteria
0, 6 and 24 month
Subjective assessment of Diverticulitis severity
Time Frame: 0, 6 and 24 month
Evaluation of the patients subjective estimate on disease severity by use of a visual analogue scale (VAS). The scale ranges from 0 to 100 mm. 0 is the least desirable condition (=most severe imaginable diverticulitis). 100 is the most desirable condition (=no diverticulitis).
0, 6 and 24 month
Diverticulitis severity: Classification of Diverticular Disease
Time Frame: 1 day before surgery
CT-scan based grading of diverticulitis in uncomplicated or complicated disease according to Classification of Diverticular Disease
1 day before surgery
Diverticulitis severity: Ambrossetti Classification
Time Frame: 1 day before surgery
CT-scan based grading of diverticulitis in uncomplicated or complicated disease according to Ambrossetti Classification
1 day before surgery
Diverticulitis severity: Modified Hinchey Classification
Time Frame: 1 day before surgery
CT-scan based grading of diverticulitis in uncomplicated or complicated disease according to Modified Hinchey Classification
1 day before surgery
Diverticulitis severity according to preoperative CT-scan
Time Frame: 1 day before surgery
Evaluation for evidence of pericolic gas
1 day before surgery
Diverticulitis severity according to preoperative CT-scan
Time Frame: 1 day before surgery
Evaluation for evidence of pericolic or pelvic abscess
1 day before surgery
Diverticulitis severity
Time Frame: 2 days after surgery
histological grading of inflammation in the resected bowel (Grade 1-4)
2 days after surgery
Influence of guideline specific treatment on postoperative quality of life
Time Frame: 6 and 24 month
Postoperative comparison of indication for surgery with given indications in relevant international Guidelines (German, US, Danish, GB, Italian, Dutch). Review of the association between a guideline-matching treatment and postoperative quality of life. Identification of the guideline, which potentially leads to the best achieved quality of life
6 and 24 month
Postoperative changes in fecal continence
Time Frame: 0, 6 and 24 month
Pre- and postoperative results of Wexner-score
0, 6 and 24 month
Postoperative changes in urinary continence
Time Frame: 0, 6 and 24 month
Pre- and postoperative results of urinary distress inventory (UDI6)
0, 6 and 24 month
Postoperative changes in male sexual function
Time Frame: 0, 6 and 24 month
Assessment of male sexual function by use of International index of erectile function (IIEF)
0, 6 and 24 month
Postoperative changes in female sexual function
Time Frame: 0, 6 and 24 month
Assessment of female sexual function by use of Female Sexual Function Index (FSFI)
0, 6 and 24 month
Preoperative fecal calprotectin
Time Frame: 1 day preoperative
Measurement of fecal calprotectin preoperatively
1 day preoperative
Postoperative fecal calprotectin
Time Frame: 6 and 24 month
Measurement of fecal calprotectin postoperatively
6 and 24 month
Morphological changes of the bowel wall
Time Frame: 1 day after surgery
Analysis at the rectosigmoidal junction: overall thickness of the bowel wall
1 day after surgery
Morphological changes of the bowel wall: thickness of bowel wall
Time Frame: 1 day after surgery
Analysis at the the rectosigmoidal junction: thickness of the muscular layer
1 day after surgery
Morphological changes of the bowel wall: Cells of Cajal
Time Frame: 1 day after surgery
Analysis within the inflamed segment: amount of Cajal-cells in the bowel wall
1 day after surgery
Morphological changes of the bowel wall: Fibrosis
Time Frame: 1 day after surgery
Analysis within the inflamed segment: Grade of fibrosis (1-4)
1 day after surgery
Cost analysis
Time Frame: baseline and 6 and 24 month
Review of disease specific health cost by request at health insurance companies
baseline and 6 and 24 month
Productivity analysis
Time Frame: baseline and 6 and 24 month
Assessment of labour productivity by use of the Productivity Cost Questionnaire (iPCQ)
baseline and 6 and 24 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Maximilian Sohn, Dr. med., Städtisches Klinikum München GmbH

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 28, 2017

Primary Completion (Estimated)

October 31, 2024

Study Completion (Estimated)

December 31, 2024

Study Registration Dates

First Submitted

April 19, 2018

First Submitted That Met QC Criteria

May 16, 2018

First Posted (Actual)

May 17, 2018

Study Record Updates

Last Update Posted (Actual)

September 8, 2023

Last Update Submitted That Met QC Criteria

September 7, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

3
Subscribe